These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 39009951)

  • 1. MHC-I and PD-L1 Expression is Associated with Decreased Tumor Outgrowth and is Radiotherapy-inducible in the Murine Head and Neck Squamous Cell Carcinoma Model MOC1.
    Boreel DF; Sandker GGW; Ansems M; van den Bijgaart RJE; Peters JPW; Span PN; Adema GJ; Heskamp S; Bussink J
    Mol Imaging Biol; 2024 Oct; 26(5):835-846. PubMed ID: 39009951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD-L1-expressing head and neck cancer.
    Jang JY; Lee BS; Huang M; Seo C; Choi JH; Shin YS; Woo HG; Kim CH
    Mol Oncol; 2024 Aug; 18(8):1923-1939. PubMed ID: 38511232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild hyperthermia upregulates PD-L1 in the tumor microenvironment and enhances antitumor efficacy of PD-L1 blockade in murine squamous cell carcinoma.
    Ohta Y; Ichimura N; Yamaguchi S; Ohara G; Yamamoto N; Itoh Y; Yamada K; Nakamura S; Hibi H
    Nagoya J Med Sci; 2024 Aug; 86(3):497-506. PubMed ID: 39355357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of immune checkpoint proteins PD-L1 and TIM3 in mouse and human head and neck squamous cell carcinoma.
    Elmusrati A; Wang CY
    Eur J Oral Sci; 2024 Oct; 132(5):e13010. PubMed ID: 39090710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
    Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
    Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brusatol improves the efficacy of an anti-mouse-PD-1 antibody via inhibiting programmed cell death 1 ligand 1 expression in a murine head and neck squamous cell carcinoma model.
    Wu Y; Zhang G; Yin P; Wen J; Su Y; Zhang X
    Arch Oral Biol; 2024 Oct; 166():106043. PubMed ID: 38968906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
    Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
    Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
    Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
    Front Immunol; 2019; 10():1644. PubMed ID: 31379843
    [No Abstract]   [Full Text] [Related]  

  • 11. Unveiling the regulatory mechanism of nimotuzumab on PD-L1 expression in head and neck squamous cell carcinoma patients: Implications for enhanced anticancer treatment strategies.
    Hu M; Tang B; Dai Y; Zhao X
    Cell Signal; 2024 Sep; 121():111290. PubMed ID: 38977231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation.
    Kenison JE; Wang Z; Yang K; Snyder M; Quintana FJ; Sherr DH
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33941684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
    Tsai MS; Chen WC; Lu CH; Chen MF
    Oral Oncol; 2019 Apr; 91():47-55. PubMed ID: 30926062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer cell-specific PD-L1 expression is a predictor of poor outcome in patients with locally advanced oral cavity squamous cell carcinoma.
    Wang M; Qin L; Thia K; Nguyen T; MacDonald S; Belobrov S; Kranz S; Goode D; Trapani JA; Wiesenfeld D; Neeson PJ
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39357980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunomodulatory ballet of tumour-derived extracellular vesicles and neutrophils orchestrating the dynamic CD73/PD-L1 pathway in cancer.
    Rubenich DS; Domagalski JL; Gentil GFS; Eichberger J; Fiedler M; Weber F; Federlin M; Poeck H; Reichert TE; Ettl T; Bauer RJ; Braganhol E; Schulz D
    J Extracell Vesicles; 2024 Jul; 13(7):e12480. PubMed ID: 38978304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of downregulating FEN1 and PD-1 blockade enhances antitumor activity of CD8+ T cells against HNSCC cells in vitro.
    Wang X; Xu S; Fu T; Wu Y; Sun W
    J Oral Pathol Med; 2023 Oct; 52(9):834-842. PubMed ID: 37728572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
    Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
    Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.